Join
Live feed
·
PRReleasevia Quantisnow
Dogwood Therapeutics Inc. logo

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

ByQuantisnow·Wall Street's wire, on your screen.
DWTX· Dogwood Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DWTX (Dogwood Therapeutics Inc.) and more on Quantisnow.